Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Nephrology
•
Glomerulonephritis
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
Related Questions
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
When would you recommend starting immunosuppression in patients diagnosed with Henoch-Schönlein purpura and IgA nephropathy who have proteinuria < 1 gram per day and eGFR > 60 mL/min who are already on ACEi and SGLT2i?
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
How long do you continue maintenance immunosuppression in a patient with PR3 ANCA glomerulonephritis with pulmonary involvement?
What is your approach to the use of immunosuppression for patients with poststreptococcal glomerulonephritis?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
What is your preferred initial therapy for patients with IgA nephropathy and more than 1 gram of proteinuria, given the recent approvals of sparsentan and budesonide alongside existing options like prednisone and ACEi/ARBs?
Would you recommend genetic testing to determine if there is a potential underlying primary process in a patient with congenital solitary kidney who is presumed to have secondary FSGS?